LIDODERM is recommended as a first-line treatment for PHN pain by respected third parties – alone or with oral analgesics1,2,3







a Level A rating establishes a therapy as effective, ineffective, or harmful for the given condition in the specified population based on at least 1 convincing class I study or at least 2 consistent, convincing class II studies. Class I studies are prospective, randomized, controlled clinical trials with masked outcome assessments in representative populations. Class II studies are prospective,matched-group, cohort studies in representative populations withmasked outcome assessments thatmeet predefined criteria, or randomized, controlled trials in representative populations that lack one of the predefined criteria.


REFERENCES
  1. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-251.
  2. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain.. 2005;118:289-305.
  3. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia. An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63:959-965.